Medicine and Dentistry
Ovarian Cancer
100%
Malignant Neoplasm
98%
Overall Survival
67%
Uterine Cancer
52%
Neoplasm
31%
Diseases
26%
Cohort Analysis
23%
Krukenberg Tumor
23%
Biological Marker
21%
Microtubule
19%
Hazard Ratio
19%
Epothilone B
19%
Radiation Therapy
19%
Tubulin
19%
Recurrent Disease
19%
Breast Cancer
18%
Cervical Cancer
18%
Cancer Cell
17%
Progression Free Survival
17%
Pelvis
16%
Carcinosarcoma
16%
Hysterectomy
15%
Cancer
15%
Metastatic Carcinoma
15%
Colorectal Carcinoma
14%
In Vitro
14%
Adenocarcinoma
14%
Lymph Node
14%
Angioleiomyoma
14%
Retroperitoneal Lymph Node Dissection
13%
Cytoreductive Surgery
13%
Prognostic Factor
12%
Female Genital Tract Cancer
12%
Adjuvant Chemotherapy
12%
Messenger RNA
11%
Base
11%
Proportional Hazards Model
11%
Drug Resistance
10%
Tumor Antigen
10%
Clinical Trial
9%
Cytotechnology
9%
Brachytherapy
9%
Debulking Surgery
9%
Neoadjuvant Chemotherapy
9%
Human Epididymis Protein 4
9%
Down Syndrome
9%
Pelvic Exenteration
9%
Initiation Factor
9%
Prenatal Diagnosis
9%
Ascites Fluid Cytology
9%
Keyphrases
Ovarian Cancer
75%
Overall Survival
64%
National Cancer Database
55%
Chemotherapy
33%
Down Syndrome
32%
Database Study
28%
Tubulin
27%
Hazard Ratio
25%
Endometrial Cancer
22%
Matched Cohort Analysis
18%
TUBB3
18%
Ovarian Cancer Cells
17%
Confidence Interval
17%
Hyperglycosylated hCG
17%
Adjuvant Chemotherapy
16%
Ovarian Cancer Patients
15%
Breast Cancer
15%
Progression-free Survival
15%
Radiotherapy
15%
Cervical Cancer
14%
Epothilone B
14%
Hyperglycosylated Human Chorionic Gonadotropin
14%
Improved Survival
14%
High-grade Serous Ovarian Cancer (HGSOC)
14%
Hysterectomy
13%
Tumor
12%
Lymphadenectomy
12%
Prognostic Factors
12%
Core Fragment
12%
Endometrioid Endometrial Cancer
12%
Epithelial Ovarian Cancer
11%
Time Ratio
11%
Advanced Ovarian Cancer
11%
Leiomyosarcoma
10%
Cancer Aggressiveness
10%
Screening Test
10%
Distant Metastasis
10%
Uterine Serous Carcinoma
10%
Colorectal Cancer
10%
Pregnant Women
10%
Non-associated
10%
Lymph Node Ratio
10%
Immunoassay
9%
Drug Target
9%
Tumor Size
9%
During Pregnancy
9%
Surgical Staging
9%
Human Epididymis Protein 4
9%
Pelvic Exenteration
9%
Tumor Protein p53 (TP53)
9%